CARVYKTI sol inj 2.1-39 × 10e6 ml 1x30oder70ml pce

7680679560017 CH-67956 L01XL05 07.16.4.
CARVYKTI sol inj 2.1-39 × 10e6 ml 1x30oder70ml pce
CARVYKTI sol inj 2.1-39 × 10e6 ml 1x30oder70ml pce
1 / 2
google

Details

GTIN
7680679560017
Pharmacode
-
Product number
6795601
CPT
-
Packaging group
1x30 oder 70ml
Unit
Beutel
Composition
Suspension: ciltacabtagenum autoleucelum 3.2x10^6-1x10^8 CAR+ T-Zellen, CryoStor CS5, ad praeparationem pro.

Articles (1)

Carvykti, Infusionsdispersion
Beutel
1x30 oder 70ml
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
09/10/2026
Professional SmPC
Français
09/10/2026
Professional SmPC
Italien
09/10/2026
Patient information leaflet
Allemand
28/10/2025
Patient information leaflet
Français
28/10/2025
Patient information leaflet
Italien
28/10/2025

Detailed composition

Substance Quantity Type Category
ciltacabtagenum autoleucelum
- Substance Wirkstoff (Principe actif)
CryoStor CS5
- Substance HIMDK

Authorization holder

Janssen-Cilag AG

6300 Zug

Authorization information

Swissmedic authorization number
67956
Drug name
Carvykti, Infusionsdispersion
Galenic form
INLFS
ATC Code
L01XL05
Authorization status
Z
Dispensation category
A
First authorization
08/08/2022
Authorization expiration date
07/08/2027
IT number
07.16.4.
Domain
Human medicine
Field of application
Carvykti ist für die Behandlung von erwachsenen Patienten mit rezidiviertem und refraktärem multiplem Myelom indiziert, die zuvor mindestens zwei Therapielinien erhalten haben, inklusive einem immunmodulatorischen Wirkstoff, einem Proteasom-Inhibitor und einem Anti-CD38-Antikörper, und welche refraktär zu Lenalidomid sind.

Packaging details

Description (FR)
CARVYKTI sol inj 2.1-39 × 10e6 ml 1x30oder70ml pce
Description (DE)
CARVYKTI Inj Lös 2.1-39 × 10e6 ml 1x30oder70ml Stk
Market launch
03/09/2024
Narcotic (BTM)
No

Application methods

IV

Other packaging sizes

Buy us a coffee Explore the data